chapter thirteen

13 Multimodal AI Systems for End-to-End Drug Discovery

 

This chapter covers

  • Orchestrating diverse AI models into unified, end-to-end discovery workflows.
  • Architectural patterns for connecting predictive and generative components.
  • Implementing closed-loop active learning cycles to refine model performance.
  • Real-world case studies spanning target discovery to clinical trials.
  • Critical assessment of clinical outcomes, challenges, and future trends.

Having established the fundamental building blocks of computational discovery in preceding chapters, we now turn to the "fourth wave" of innovation: integrated multimodal AI systems. This chapter examines how production-ready platforms orchestrate diverse models—spanning genomics, protein structure, and small molecule design—into cohesive, end-to-end workflows that accelerate the journey from target identification to clinical trials. We will explore how these systems leverage closed-loop feedback to continuously refine their predictions based on experimental data, transforming isolated tools into autonomous engines capable of navigating the complex, multi-objective landscape of pharmaceutical research.

13.1 From Components to Systems: The Integration Challenge

13.1.1 The Evolution of AI-Driven Drug Discovery

13.1.2 Defining Multimodal AI Systems

13.2 Platform Architecture & Components

13.2.1 Platform Overview

13.2.2 Integration Patterns Across Platforms

13.2.3 Integrating Multimodal Representations

13.3 End-to-End Workflows in Practice

13.3.1 Case Study 1: Rentosertib for Idiopathic Pulmonary Fibrosis

13.3.2 Case Study 2: Virtual Screening at Billion-Compound Scale

13.3.3 Case Study 3: Protein Therapeutic Design - A Multi-Model Workflow

13.4 Clinical Translation: Hype vs. Reality

13.4.1 What AI Has Improved

13.4.2 What AI Has Not Solved

13.4.3 Current Limitations and Challenges

13.4.4 Future Directions (2023-2030)

13.4.5 Final Comments

13.5 Summary

13.6 References